Sign In
- Home
- Share Prices
- AQSE Share Prices
- Euronext
- US Share Prices
- Stock Tips
- Share Chat
- FX
- News & RNS
- Media
- Trading Brokers
- Finance Tools
- Members
Latest Share Chat
Faron Pharmaceuticals Share News (FARN)
FARN Share
Price
FARN Share
News
FARN Share
Chat
FARN Share
Trades4
FARN
Live RNS
FARN Share
Charts
FARN Level 2
Console
FARN Live
Share Price
FARN Broker
Ratings
FARN Directors
Deals
FARN Financial
Diary
FARN
Fundamentals
FARN Short
Positions
FARN
Media
FARN Company
Research
FARN Company
Timeline
Share Price Information for Faron Pharmaceuticals (FARN)
Last checked at -
Last checked at 
Intraday Faron Pharmaceuticals Share Chart
Faron Pharmaceuticals Notes Study Supporting Clevegen Programme
LONDON (Alliance News) - Faron Pharmaceuticals Oy on Monday said an article published in the Journal of Immunology has outlined the functional role of the company's Clever-1 treatment, part of its Clevegen cancer immunotherapy antibody programme.
Faron, which floated in London earlier this month, said the data published in the study supported Clever-1 as an immuosuppresive molecule and supports the use of Clevegen as an immunotherapy product.
"We are working hard to advance our Clevegen programme, as announced recently, towards clinical use as a new onco-immunological alternative," said Faron Chief Executive Markku Jalkanen.
Shares in Faron were trading flat at 275.00 pence on Monday.
By Sam Unsted; samunsted@alliancenews.com; @SamUAtAlliance
Copyright 2015 Alliance News Limited. All Rights Reserved.
Latest FARN News
- Faron Raises EUR14 Million In Oversubscribed Share Placing
22 Apr 2020 - Faron Pharmaceuticals Plans Private Placing To Raise EUR10 Million
21 Apr 2020 - UK TRADING UPDATE SUMMARY: Watkin Jones Cancels Payout, Halts Work
1 Apr 2020 - Research And Development Expense Drop Cuts Faron Pharmaceuticals Loss
20 Mar 2020 - UK WINNERS & LOSERS SUMMARY: Future Surges As It Sees Results In Line
20 Mar 2020 - UK Earnings, Trading Statements Calendar - Next 7 Days
13 Mar 2020 - Faron Pharmaceuticals Gets Green Light For New Traumakine Trial
9 Mar 2020 - Faron gets FDA tick from proposed design of next 'Traumakine' study
9 Mar 2020
Related News
IN BRIEF: Faron Pharmaceuticals fined EUR30,000 by Nasdaq Helsinki
Faron Pharmaceuticals Ltd - Turku, Finland-based cancer drug developer - Says the Disciplinary Committee of Nasdaq Helsinki Ltd has imposed an EUR30,0...
WINNERS & LOSERS: James Cropper sees earnings up; Block sells stake
(Alliance News) - The following are the leading risers and fallers among London Main Market small-cap and AIM stocks on Tuesday.
Faron Pharmaceuticals News
Faron Raises EUR14 Million In Oversubscribed Share Placing
Faron Raises EUR14 Million In Oversubscribed Share Placing
Faron Pharmaceuticals Plans Private Placing To Raise EUR10 Million
Faron Pharmaceuticals Plans Private Placing To Raise EUR10 Million
UK TRADING UPDATE SUMMARY: Watkin Jones Cancels Payout, Halts Work
UK TRADING UPDATE SUMMARY: Watkin Jones Cancels Payout, Halts Work
Research And Development Expense Drop Cuts Faron Pharmaceuticals Loss
Research And Development Expense Drop Cuts Faron Pharmaceuticals Loss
UK WINNERS & LOSERS SUMMARY: Future Surges As It Sees Results In Line
UK WINNERS & LOSERS SUMMARY: Future Surges As It Sees Results In Line
UK Earnings, Trading Statements Calendar - Next 7 Days
UK Earnings, Trading Statements Calendar - Next 7 Days
Faron Pharmaceuticals Gets Green Light For New Traumakine Trial
Faron Pharmaceuticals Gets Green Light For New Traumakine Trial
Faron gets FDA tick from proposed design of next 'Traumakine' study
(Sharecast News) - Faron Pharmaceuticals announced on Monday that the US Food and Drug Administration (FDA) has accepted its proposed protocol design ...
Follow the stocks
